Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer [2]

Lung Cancer

Volumn 50, Issue 3, 2005, Pages 417-418

  Viswanathan, Avinash ^a   Pillot, Giancarlo ^a   Govindan, Ramaswamy ^a,b  

^a USA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; GEFITINIB; METHIONINE; THREONINE;

ADVANCED CANCER; DEMOGRAPHY; DISEASE COURSE; DRUG RESPONSE; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; TREATMENT FAILURE;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33644506118     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.07.004     Document Type: Letter

References (7)

1. R. Perez-Soler, A. Chachoua, L.A. Hammond, E.K. Rowinsky, M. Huberman, and D. Karp Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 2004 3238 3247
2. M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, and J.Y. Douillard Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol 21 2003 2237 2246
3. M.G. Kris, R.B. Natale, R.S. Herbst, T.J. Lynch Jr., D. Prager, and C.P. Belani Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer, a randomized trial JAMA 290 2003 2149 2158
4. F. Shepherd, J. Pereira, T. Ciuleanu, E.H. Tan, V. Hirsh, and S. Thongprasert A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial Proc Am Soc Clin Oncol 2004 22
5. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, and I. Sarkaria EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 2004 13306 13311
6. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, and B.W. Brannigan Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
7. S. Kobayashi, T.J. Boggon, T. Dayaram, P.A. Janne, O. Kocher, and M. Meyerson EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 2005 786 792